human
rhinoviru
rv
infect
emerg
import
trigger
exacerb
chronic
respiratori
diseas
includ
asthma
chronic
obstruct
pulmonari
diseas
copd
cystic
fibrosi
cf
interstiti
lung
diseas
ild
includ
idiopath
pulmonari
fibrosi
ipf
epidemiolog
studi
play
central
part
understand
associ
rv
respiratori
virus
exacerb
chronic
respiratori
diseas
chapter
offer
summari
epidemiolog
literatur
link
rv
infect
acut
exacerb
tabl
refer
key
refer
establish
import
rv
infect
exacerb
chronic
respiratori
diseas
rang
postul
mechan
rv
infect
elicit
complex
host
respons
part
may
actual
contribut
diseas
patholog
perpetu
symptom
rather
prevent
viru
infect
associ
symptom
whether
rv
infect
directli
trigger
event
add
synerg
chang
natur
host
respons
drive
diseas
whether
underli
diseas
make
certain
individu
suscept
rv
infect
pertin
question
field
chapter
includ
indepth
commentari
reason
rv
common
viral
pathogen
associ
exacerb
diseas
includ
impact
current
emerg
treatment
outcom
rv
infect
diseas
progress
final
explor
potenti
new
therapeut
opportun
better
manag
chronic
respiratori
diseas
whilst
minim
acut
chronic
diseas
promot
effect
rv
infect
asthma
chronic
diseas
conduct
airway
character
airway
hyperreact
caus
revers
airway
smooth
muscl
asm
mediat
bronchoconstrict
anoth
defin
featur
asthma
airway
inflamm
perpetu
airway
hyperreact
well
mucu
product
togeth
airway
inflamm
caus
airway
narrow
airway
obstruct
resist
airflow
symptom
asthma
link
numer
stimuli
includ
airway
infect
variou
allergen
exposur
airborn
pollut
exercis
stress
nervou
provoc
key
featur
asthma
decreas
lung
function
measur
spontan
chang
peak
expiratori
flow
pef
decreas
forc
expiratori
volum
second
follow
provoc
symptom
includ
nocturn
awaken
dyspnea
wheez
tighten
chest
immedi
effect
asthma
gener
revers
shortact
agonist
asthma
consid
heterogen
complex
diseas
present
chronic
stabl
diseas
differ
highlight
import
virus
particularli
rv
associ
ae
wheez
event
children
corn
ae
show
frequenc
rv
infect
asthmat
sever
longer
durat
symptom
versu
nonasthmat
johnston
ae
identifi
virus
particularli
rv
vector
septemb
asthma
epidem
northern
hemispher
bonnelykk
aewheez
demonstr
link
variant
recurr
ae
wheez
children
seemung
copd
demonstr
associ
rv
copd
diseas
sever
papi
copd
show
rv
readili
viru
detect
copd
versu
stabl
copd
bafadhel
copd
show
rv
associ
copd
ere
associ
certain
biomark
serum
collinson
cfe
show
associ
picornavirus
cf
diseas
sever
bacteri
infect
cfe
wootton
ipf
show
virus
includ
rv
associ
ipf
stabl
diseas
sever
includ
mild
moder
sever
respons
treatment
glucocorticosteroid
gc
bronchodil
may
also
vari
categor
well
partial
poorli
control
common
endophenotyp
associ
allerg
asthma
defin
physician
diagnosi
asthma
often
associ
high
serum
immunoglobulin
e
ige
level
posit
skin
prick
test
aeroallergen
andor
confirm
diagnosi
atop
disord
allerg
rhiniti
evid
interleukin
il
driven
inflamm
increas
level
eosinophil
blood
lower
airway
sampl
high
level
feno
may
also
confirm
associ
asthma
asthma
endophenotyp
may
exist
includ
adultonset
asthma
steroid
resist
poorli
steroid
respons
neutrophil
asthma
fix
airflow
limit
asthma
simpli
term
type
low
asthma
howev
well
defin
genet
analysi
biomark
allerg
asthma
current
exact
natur
exist
subgroup
vigor
debat
erron
diagnosi
effect
treatment
confound
led
lack
consensu
identif
correct
asthma
endophenotyp
implement
precis
medicin
approach
repres
import
ongo
challeng
field
asthma
exacerb
ae
defin
stabl
individu
asthma
suddenli
becom
uncontrol
experi
increas
symptom
result
gener
practition
gp
consult
hospit
addit
treatment
includ
oral
gc
unit
state
approxim
emerg
room
visit
associ
asthma
year
approxim
asthmat
individu
least
one
ae
per
year
ae
may
multipl
predictor
howev
recent
ae
histori
strongest
predictor
futur
ae
event
children
number
allerg
sensit
trigger
race
import
predictor
ae
common
individu
poor
lung
function
classifi
sever
difficult
treat
asthma
may
compris
asthmat
ae
may
life
threaten
result
signific
morbid
worldwid
includ
schoolstudi
absente
sick
leav
recent
econom
studi
shown
individu
suffer
ae
increas
total
healthcar
asthma
specif
healthcar
cost
compar
individu
experi
ae
unadjust
total
cost
individu
experi
ae
may
accru
cost
usd
per
year
compar
approxim
usd
per
year
individu
ae
trigger
mani
factor
howev
respiratori
viru
infect
common
associ
ae
adult
children
histor
detect
method
virus
respiratori
clinic
sampl
nasal
secret
throat
swab
reli
vitro
cell
cultur
base
method
approach
limit
least
inabl
propag
mani
clinic
import
virusesinclud
signific
number
approxim
base
current
classif
rv
know
belong
rvc
speci
nucleic
acid
base
molecular
method
becom
method
choic
recent
year
next
gener
sequenc
dna
protein
base
viruschip
method
becom
avail
ad
advantag
potenti
discrimin
differ
virus
kind
virus
often
detect
respiratori
sampl
obtain
ae
includ
respiratori
syncyti
virus
rsv
influenza
virus
adenovirus
human
rv
coronavirus
parainfluenza
virus
piv
well
recent
identifi
metapneumovirus
bocavirus
howev
less
common
among
respiratori
virus
rv
common
virus
detect
typic
account
virusinduc
ae
fig
although
number
high
differ
detect
rate
involv
volunt
demograph
includ
age
geographi
method
detect
differ
rv
genotyp
rva
rvc
commonli
associ
ae
rvb
rvc
group
show
uniqu
sequenc
ldl
receptor
bind
site
initi
suggest
uniqu
receptor
sinc
identifi
cadherinrel
famili
member
rvc
may
contain
group
virus
associ
sever
ae
event
requir
hospit
although
occur
unknown
epidemiolog
studi
shown
northern
hemispher
rv
infect
result
mark
increas
emerg
room
admiss
due
ae
fact
asthma
epidem
shown
coincid
labor
day
canada
third
week
septemb
approxim
week
children
return
school
highlight
import
role
school
age
children
vector
rv
induc
ae
strong
associ
rv
infect
ae
event
epidemiolog
studi
investig
viru
detect
rate
hospit
case
ae
definit
prove
rv
caus
ae
infer
mechan
import
highlight
import
connect
viral
infect
asthma
recent
human
experiment
infect
model
rva
asthmat
mous
model
allergen
exposur
rv
infect
also
establish
thu
definit
show
abil
rv
infect
contribut
lower
airway
inflamm
induc
chang
lung
function
consist
symptomolog
observ
natur
occur
ae
copd
progress
respiratori
condit
caus
exposur
cigarett
smoke
part
world
biomass
fuel
burn
character
chronic
inflamm
small
airway
acceler
loss
lung
function
andor
emphysemat
diseas
associ
airflow
limit
signific
sourc
morbid
term
mortal
worldwid
copd
current
third
lead
caus
noncommunic
death
exact
preval
copd
difficult
accur
assess
inde
number
vari
million
still
referenc
howev
recent
updat
global
burden
diseas
led
agre
number
million
peopl
copd
worldwid
includ
million
men
million
women
exact
threshold
durationintens
cigarett
smoke
result
copd
vari
individu
absenc
predispos
factor
eg
genet
environment
occup
smoke
less
packyear
cigarett
unlik
result
copd
altern
singl
best
predictor
airflow
obstruct
histori
packyear
smoke
posit
likelihood
ratio
ci
case
chronic
lung
condit
diseas
cours
includ
chronic
respiratori
symptom
wheez
breathless
punctuat
period
increas
symptomatolog
known
acut
exacerb
acut
exacerb
copd
signific
event
copd
acceler
diseas
progress
impair
qualiti
life
predomin
caus
mortal
addit
often
necessit
unschedul
healthcar
visit
treatment
cost
hospit
account
billion
direct
cost
annual
unit
state
alon
prevent
copd
major
unmet
therapeut
goal
crucial
step
toward
goal
recognit
acut
exacerb
commonli
due
respiratori
viru
infect
specif
rv
follow
host
immun
respons
viru
infect
may
impair
better
understand
immun
respons
differ
copd
compar
smoker
healthi
individu
potenti
lead
develop
new
therapi
histor
main
caus
copd
consid
bacteri
infect
belief
reflect
continu
extens
use
antibiot
copd
exacerb
despit
weak
evid
efficaci
earlier
studi
use
diagnost
techniqu
cultur
detect
viral
infect
minor
copd
exacerb
result
focu
bacteria
howev
rv
difficult
cultur
standard
assay
serolog
practic
due
presenc
serotyp
strain
nonserotyp
strain
therefor
without
polymeras
chain
reaction
pcr
virus
easili
identifi
result
earli
studi
use
diagnost
method
underestim
preval
virus
detect
copd
exacerb
rv
preval
asthma
ultim
proof
causat
rv
infect
induct
copd
come
human
model
experiment
rv
infect
copd
rv
identifi
commun
treat
mild
exacerb
hospit
patient
sever
exacerb
requir
intens
care
viru
infect
rate
acut
exacerb
unlik
repres
chronic
infect
season
carriag
viral
pcr
rare
posit
patient
sampl
prior
exacerb
timematch
control
whilst
studi
support
causal
relationship
exclud
secondari
causat
eg
bacteri
coinfect
air
pollut
novel
experiment
infect
studi
use
rv
copd
subject
show
clear
increas
lower
respiratori
tract
symptom
follow
inocul
along
airflow
obstruct
system
airway
inflamm
mimick
copd
observ
natur
occur
infect
inde
experiment
infect
studi
rv
infect
copd
subject
copd
exacerb
criteria
met
suggest
viru
detect
frequenc
report
natur
occur
exacerb
actual
gross
underestim
true
frequenc
virus
precipit
exacerb
experiment
infect
model
rv
rna
present
upper
respiratori
tract
prior
progress
lower
airway
caus
copd
exacerb
onset
therebi
exclud
secondari
causat
moreov
studi
demonstr
tempor
relationship
viral
replic
airway
symptom
exacerb
onset
viral
clearanc
exacerb
resolut
viru
load
also
correl
marker
inflamm
oxid
nitros
stress
airway
therefor
studi
provid
compel
evid
field
rv
infect
directli
link
copd
cf
common
mendelian
autosom
recess
genet
disord
affect
individu
worldwid
culpabl
gene
variant
identifi
common
wide
studi
predominantli
found
popul
northern
european
heritag
whilst
individu
cf
region
wider
rang
mutat
mutat
much
less
preval
mutat
gene
lead
defect
function
cf
transmembran
conduct
regul
cftr
protein
pulmonari
involv
promin
manifest
diseas
due
tenaci
mucu
secret
decreas
mucociliari
clearanc
result
inflamm
recurr
infect
respiratori
infect
lead
caus
acut
exacerb
result
morbid
declin
lung
function
hospit
predomin
caus
infecti
complic
cf
consid
bacteri
infect
pseudomona
aeruginosa
common
organ
cultur
role
dysfunct
ctfr
protein
play
key
role
defici
innat
immun
p
aeruginosa
infect
due
result
increas
innat
inflamm
owe
disrupt
lipid
metabol
enhanc
interact
p
aeruginosa
epitheli
cell
direct
role
cftr
bacteri
clearanc
subsequ
cftrmediat
epitheli
cell
ingest
rel
littl
publish
work
role
rv
infect
cf
exacerb
cfe
recent
studi
suggest
viral
infect
signific
impact
thu
role
respiratori
virus
like
significantli
underestim
past
exampl
prior
util
modern
pcr
techniqu
studi
reli
serolog
cultur
immunofluoresc
implic
viral
caus
exacerb
cf
patient
howev
pcr
studi
increas
detect
rate
exacerb
patient
compar
patient
stabl
condit
rv
specif
identifi
cf
patient
acut
respiratori
ill
associ
wors
respiratori
symptom
airway
function
deterior
greater
incid
secondari
bacteri
infect
compar
match
uninfect
patient
number
differ
viral
speci
detect
cf
patient
common
rv
influenza
virus
rsv
interestingli
rate
viral
infect
children
cf
elev
comparison
healthi
children
importantli
sever
clinic
ill
associ
infect
demonstr
greater
case
airway
diseas
viral
infect
associ
declin
lung
function
sever
clinic
ill
cf
indic
contribut
diseas
progress
demonstr
need
research
field
field
ild
includ
plethora
differ
individu
condit
exhibit
vari
expect
prognos
diseas
cours
common
ild
ipf
ipf
affect
approxim
million
peopl
worldwid
incid
increas
dramat
age
report
median
surviv
approxim
year
time
diagnosi
age
strongest
demograph
risk
factor
ipf
suggest
acceler
lung
age
drive
forc
develop
pathogenesi
ipf
develop
area
much
debat
sequenc
three
pathophysiolog
stage
describ
see
tabl
howev
import
clarifi
individu
predisposit
stage
go
exhibit
clinic
detect
diseas
similarli
patient
ipf
develop
stage
sequenti
order
establish
diseas
detect
asthma
copd
cf
diseas
cours
ipf
commonli
exhibit
stabl
period
punctuat
acut
exacerb
symptom
associ
stepwis
declin
lung
function
proport
episod
may
result
sequela
infect
detect
due
late
present
limit
microbiolog
detect
method
studi
natur
occur
exacerb
conclud
virus
account
small
number
event
epidemiolog
evid
infect
etiolog
ipf
exacerb
ipf
origin
work
demonstr
ipf
significantli
common
winter
spring
month
patient
take
immunosuppress
medic
ipf
increas
risk
pulmonari
infect
fourfold
although
unclear
mani
viral
moreov
commun
acquir
pneumonia
viral
bacteri
associ
higher
mortal
ild
otherwis
healthi
control
import
viral
infect
diseas
progress
ild
indirectli
support
small
trial
antivir
therapi
two
case
describ
tang
et
al
posit
ebv
pcr
sputum
sampl
treat
valacyclovir
went
exhibit
stabil
least
one
two
case
trial
ganciclovir
patient
sever
ipf
posit
ebv
serolog
brought
improv
patient
term
three
fvc
shuttl
walk
test
dtpa
scan
steroid
dose
small
sampl
size
lack
control
group
openlabel
design
make
difficult
draw
conclus
studi
optim
durat
therapi
also
unclear
patient
respond
patient
respond
die
within
month
studi
necessari
establish
true
burden
consequ
rv
particularli
given
pauciti
effect
treatment
ipf
chronic
subclin
viral
infect
implic
pathogenesi
ild
exampl
virus
ebv
cmv
hepat
c
hypothesi
chronic
andor
recurr
viral
infect
induc
alveolar
endotheli
cell
injuri
turn
trigger
releas
proinflammatori
mediat
bring
increas
diseas
patholog
rv
link
exacerb
pathogenesi
key
question
therefor
properti
rv
might
contribut
diseas
mechan
certainli
common
eas
transmiss
common
cold
viru
fact
number
antigen
distinct
virus
circul
one
time
import
furthermor
factor
contribut
predomin
rv
exacerb
chronic
respiratori
diseas
broadli
describ
follow
abil
rv
induc
inflamm
nervou
provoc
airway
remodel
repair
process
airway
mucu
product
synerg
add
ongo
establish
inflamm
eg
allerg
mediat
immun
pathway
asthma
promot
contribut
secondari
bacteri
infect
degrad
antimicrobi
defens
epitheli
junction
protein
airway
barrier
integr
antimicrobi
peptid
expos
impair
aberr
host
antivir
innat
immun
either
intrins
caus
treatment
regim
like
rv
meet
one
criteria
manner
make
qualit
differ
respiratori
virus
case
asthma
rv
certain
subtyp
rv
refer
asthmagen
virus
due
abil
associ
ae
readili
respiratori
virus
one
recent
studi
rv
describ
exacerb
exist
asthma
effect
influenza
infect
term
symptom
quit
differ
system
describ
asthmaaug
influenza
infect
support
idea
natur
rv
infect
may
distinct
respiratori
virus
section
characterist
rv
infect
may
explain
predomin
exacerb
chronic
respiratori
diseas
given
due
attent
tabl
offer
summari
induct
inflamm
nervou
provoc
airway
remodel
repair
process
airway
mucu
product
key
featur
rv
respiratori
virus
promot
exacerb
abil
induc
either
lung
inflamm
nervou
provoc
case
asthma
ipf
lung
injuri
repair
remodel
mani
innat
receptor
recogn
rv
includ
tolllik
receptor
tlr
rigi
like
helicas
nucleotidebind
oligomer
domain
nod
like
receptor
activ
famili
transcript
factor
induc
proinflammatori
host
respons
gene
rv
rsv
influenza
induc
rang
proinflammatori
cytokin
chemokin
growth
factor
adhes
molecul
mucin
thu
contribut
lung
inflamm
abil
promot
lung
inflamm
import
diseas
lung
inflamm
key
includ
asthma
cf
copd
mucin
caus
mucou
plug
airway
cytokin
facilit
cellular
chemotaxi
activ
prolifer
immun
cell
infect
airway
rv
increas
airway
hyperrespons
increas
cyclooxygenas
pathway
enzym
well
character
asthma
inflamm
relev
copd
surprisingli
low
number
vitro
studi
compar
respons
cell
copd
patient
viral
infect
healthi
control
similarli
avail
studi
examin
natur
occur
virusinduc
copd
exacerb
demonstr
role
inflammatori
cell
neutrophil
eosinophil
proinflammatori
mediat
experiment
rv
infect
studi
copd
indic
rv
induc
airway
neutrophil
inflamm
innat
inflammatori
medit
gmcsf
tnf
vitro
studi
indic
enhanc
inflammatori
respons
viru
infect
copd
subject
may
one
mechan
wherebi
virus
induc
exacerb
role
neutrophil
incomplet
understood
abil
damag
tissu
contribut
airway
inflamm
undoubtedli
import
role
antibacteri
defens
may
produc
type
ifn
mous
model
may
antivir
properti
interest
recent
phase
clinic
trial
inhibitor
neutrophil
chemokin
receptor
fail
affect
sever
ae
rate
lung
function
asthma
control
questionnair
acq
score
mechan
viralinduc
cfe
increas
clinic
ill
well
character
inconsist
result
publish
studi
whilst
group
demonstr
increas
product
proinflammatori
cytokin
chemokin
airway
epitheli
cell
obtain
cf
patient
compar
healthi
control
other
fail
detect
differ
unclear
lead
contrast
observ
rv
infect
shown
damag
compromis
integr
airway
infect
airway
epitheli
cell
directli
caus
cell
death
andor
epitheli
cell
shed
also
affect
epitheli
permeabl
lead
increas
airway
inflamm
creat
opportun
increas
secondari
infect
allergen
uptak
exposur
environment
pollut
irrit
may
trigger
exacerb
chronic
respiratori
diseas
term
nervou
provoc
rv
recent
shown
upregul
transient
receptor
potenti
trp
channel
famili
member
neuroblastoma
cell
may
import
cough
respons
sensit
methacholin
observ
infect
rv
also
induc
mediat
requir
airway
repair
result
airway
scar
remodel
process
includ
angiogenesi
increas
asm
prolifer
hypertrophi
thicker
basement
membran
owe
collagen
fibronectin
deposit
well
gener
new
lymphat
vessel
ultim
result
thicker
airway
wall
reduc
lung
function
import
process
obviou
asthma
whether
rv
infect
directli
initi
process
unclear
howev
rv
induc
proangiogen
mediat
includ
fibroblast
growth
factor
vascular
endotheli
growth
factor
requir
fibrosi
ipf
structur
protein
perlecan
collagen
build
block
airway
remodel
virus
synerg
add
ongo
establish
inflamm
evid
properti
greatest
rv
infect
asthma
synergi
viral
infect
allergen
sensit
exposur
first
realiz
epidemiolog
studi
addit
evid
interact
gain
human
challeng
mous
model
rv
individu
asthma
rv
infect
bronchial
epithelium
also
like
addit
synergist
effect
allergen
sensit
challeng
epitheli
deriv
factor
thymic
stromal
lymphopoietin
activ
cell
dc
type
innat
lymphoid
cell
induc
readili
rv
infect
allow
direct
link
respiratori
viru
infect
airway
epithelium
augment
exist
pathway
asthma
whether
increas
rv
diseas
burden
asthma
simpli
result
type
skew
environ
whether
rv
contribut
type
inflamm
wider
debat
often
discuss
asthma
onset
concern
ae
rv
perhap
easili
understood
direct
contributor
establish
type
inflamm
discuss
result
tip
fine
balanc
stabl
asthma
increas
symptom
lead
ae
studi
cohabit
asthma
nonasthmat
pair
found
frequenc
rv
infect
differ
asthmat
healthi
volunt
asthmat
sever
longer
durat
lower
airway
symptom
consist
concept
individu
asthma
may
prone
greater
number
rv
infect
deal
infect
fundament
differ
manner
nonasthmat
individu
studi
use
rv
experiment
challeng
gener
show
asthmat
nonasthmat
equal
rate
success
infect
asthmat
gener
greater
lower
airway
symptom
score
increas
decreas
asthma
control
underli
type
immun
allerg
inflamm
may
influenc
cours
rv
infect
anoth
matter
discuss
detail
promot
contribut
secondari
bacteri
infect
degrad
antimicrobi
defens
abil
promot
secondari
bacteri
infect
relev
ae
wheez
children
copd
cfe
rv
disrupt
integr
airway
epithelium
reduc
antibacteri
cytokin
respons
degrad
antimicrobi
peptid
may
promot
secondari
bacteri
infect
includ
enhanc
dispers
infiltr
colon
bacteri
speci
may
alreadi
present
low
level
ae
children
rv
increas
moraxella
abund
cf
exacerb
associ
respiratori
viral
infect
associ
increas
bacteri
load
although
studi
report
associ
viral
bacteri
infect
common
copd
role
dual
previous
consid
studi
appear
indic
play
promin
role
copd
low
detect
rate
rang
howev
papi
et
al
observ
exacerb
dual
infect
sever
studi
experiment
rv
infect
secondari
bacteri
infect
detect
copd
patient
confirm
rv
infect
increas
proteobacteri
dna
sequenc
includ
potenti
pathogen
haemophilu
influenza
report
crucial
virus
bacteria
detect
separ
time
point
pattern
viru
infect
occur
first
bacteri
infect
later
implic
studi
natur
occur
exacerb
collect
sampl
singl
time
point
underestim
true
incid
dual
infect
like
miss
secondari
infect
confirm
recent
studi
natur
occur
exacerb
patient
sampl
two
time
point
exacerb
rv
initi
detect
bacteria
absent
bacteria
detect
sampl
day
also
evid
dual
infect
contribut
copd
sever
copd
patient
h
influenza
detect
exacerb
presenc
symptomat
cold
associ
higher
bacteri
load
hospit
patient
copd
dual
infect
correl
impair
lung
function
longer
hospit
stay
experiment
rv
infect
coinfect
associ
prolong
lower
respiratori
symptom
summari
role
dual
infect
copd
exacerb
like
overlook
may
import
factor
contribut
sever
copd
exacerb
expos
impair
aberr
host
antivir
innat
immun
either
intrins
caus
treatment
regim
one
exampl
chronic
respiratori
diseas
associ
way
impair
antivir
immun
strike
exampl
effect
type
mediat
allerg
inflamm
allerg
asthma
antivir
interferon
ifn
respons
defici
type
type
iii
ifn
associ
upregul
type
pathway
involv
presenc
ige
skin
prick
test
spt
eosinophil
inflamm
believ
may
root
caus
impair
antivir
immun
potenti
result
higher
viru
load
ultim
increas
symptom
wors
lung
function
sever
studi
observ
impair
ifn
cell
deriv
peopl
asthma
studi
observ
differ
could
account
differ
cultur
method
viru
stock
asthma
sever
unappreci
subtl
differ
asthma
endophenotyp
donor
support
ex
vivo
find
viru
load
higher
individu
atop
asthma
compar
nonasthmat
follow
experiment
rv
challeng
recent
bronchial
epitheli
stain
immunohistochemistri
impair
individu
atop
asthma
invers
relat
increas
clinic
symptom
increas
viru
load
follow
experiment
rv
challeng
mechan
associ
impair
ifn
includ
crosslink
ige
dc
deriv
peopl
asthma
prevent
virusinduc
product
bec
deriv
peopl
asthma
shown
higher
express
level
suppressor
cytokin
nuclear
prevent
virusinduc
product
macrophag
may
recogn
respiratori
virus
via
express
defici
macrophag
bronchial
tissu
peopl
asthma
may
explain
cell
also
impair
ifn
product
viral
infect
direct
cell
cultur
base
studi
ifn
transcript
protein
measur
follow
ex
vivo
viru
infect
altern
method
perceiv
impair
ifn
individu
asthma
use
larg
transcriptom
studi
studi
advantag
often
incorpor
donor
possibl
cultur
base
studi
recent
studi
investig
gene
express
pattern
bronchial
brush
gene
strongli
correl
feno
level
use
identifi
clinic
import
cluster
asthma
phenotyp
although
type
iii
ifn
downstream
gene
form
identifi
cluster
group
individu
high
express
gene
associ
type
immun
also
found
low
express
level
gene
relat
innat
immun
antimicrobi
defens
fact
sampl
taken
stabl
asthma
exacerb
like
explain
lack
type
iii
ifn
relat
gene
found
associ
cluster
asthma
phenotyp
idea
type
inflamm
may
relat
impair
ifn
correct
associ
increas
sever
rv
infect
ae
could
explain
type
inflammatori
environ
provid
suscept
factor
rv
infect
epidemiolog
studi
respiratori
viru
infect
exact
endophenotyp
asthma
seldom
studi
detail
data
ifn
express
therefor
idea
remain
compel
hypothesi
support
recent
studi
children
birth
cohort
studi
found
cluster
analysi
ex
vivo
respons
peripher
blood
mononuclear
cell
pbmc
age
differ
virus
tlr
ligand
relat
asthma
age
age
one
cluster
defin
low
type
ifn
induct
high
proinflammatori
cytokin
induct
strongest
relationship
asthma
risk
frequenc
ae
unschedul
visit
primari
health
servic
associ
asthma
impair
ifn
asthma
controversi
topic
may
present
yet
properli
classifi
endophenotyp
type
asthma
phenomenon
bring
new
avenu
therapi
includ
ifn
therapi
asthma
discuss
impair
product
ifn
may
increas
suscept
viru
infect
copd
experiment
rv
infect
studi
copd
viru
load
higher
copd
subject
compar
noncopd
subject
suggest
mechan
control
viral
replic
defect
copd
subject
inocul
intranas
viru
dose
despit
remain
unclear
whether
product
ifn
impair
copd
patient
ex
vivo
rv
stimul
macrophag
copd
subject
produc
less
ifn
compar
noncopd
subject
howev
studi
support
observ
similar
even
increas
ifn
product
report
cell
obtain
copd
subject
recent
studi
also
observ
impair
induct
respons
influenza
viru
infect
failur
robustli
induc
transcript
thought
due
lack
protein
kinas
r
express
lack
format
enhanceosom
promot
presenc
rv
cf
exacerb
may
also
attribut
impair
antivir
immun
one
possibl
cf
epithelium
intrins
proinflammatori
altern
antivir
innat
immun
respons
cf
cell
inher
defici
zheng
et
al
support
premis
impair
innat
host
defens
caus
suscept
viral
infect
patient
cf
highlight
increas
replic
follow
piv
infect
cultur
airway
epitheli
cell
cf
donor
correct
subsequ
administr
although
ifn
respons
impair
reduc
induct
nitric
oxid
synthas
cf
airway
epitheli
cell
import
requir
product
nitric
oxid
known
antivir
mediat
therefor
impair
synthesi
may
one
mechan
impair
antivir
host
respons
cf
holtzman
et
al
hypothes
hypersuscept
viru
infect
via
defect
ifn
pathway
unifi
pathway
asthma
copd
cf
overrid
hypothesi
chronic
airway
inflamm
regardless
origin
interfer
innat
immun
caus
suboptim
blunt
antivir
respons
lead
imbalanc
host
respons
reinforc
preexist
predomin
inflammatori
phenotyp
viral
exacerb
ipf
may
also
result
impair
antivir
immun
studi
famili
ipf
identifi
one
way
antivir
immun
affect
ild
genet
studi
six
affect
famili
identifi
gene
work
demonstr
involv
type
iii
ifn
induct
respons
activ
import
part
innat
immun
respons
virus
includ
rv
medic
use
treat
patient
chronic
respiratori
diseas
affect
immun
airway
function
therefor
potenti
modifi
respons
rv
affect
diseas
outcom
associ
rv
infect
current
therapi
use
may
broadli
divid
two
main
group
firstli
rv
respiratori
virus
may
benefit
direct
action
therapi
exampl
suppress
import
host
respons
direct
antivir
effect
anoth
confound
therapi
use
may
promot
coincid
unknown
risk
suscept
factor
eg
antibiot
surprisingli
littl
attent
paid
detriment
effect
current
treatment
chronic
respiratori
diseas
may
antivir
host
respons
treatment
effect
may
immun
relev
viral
bacteri
infect
chronic
respiratori
diseas
discuss
gc
agonist
leukotrien
receptor
antagonist
exampl
immunomodulatori
antiinflammatori
medic
wide
use
treat
chronic
respiratori
diseas
particularli
asthma
copd
asthma
chronic
diseas
often
requir
daili
treatment
rang
immunomodulatori
immunosuppress
agent
gc
idea
seem
plausibl
hypogammaglobulinemia
associ
gc
use
asthmat
although
whether
contribut
increas
infect
clear
gc
agonist
inhibitor
potent
suppress
effect
ifn
seen
tissu
cultur
experi
recent
singanayagam
et
al
show
mous
model
gc
fluticason
propion
could
suppress
ifn
induct
antibacteri
immun
lead
increas
virusinduc
mucin
express
rv
replic
ipf
degre
ipf
due
impair
immun
respons
aris
ild
oppos
immunosuppressiveantifibrot
treatment
mani
patient
given
eg
gc
difficult
differenti
research
ild
complic
heterogen
disord
short
time
frame
avail
treatment
year
rel
imprecis
diagnost
criteria
antibiot
may
act
confound
may
associ
respiratori
infect
hygien
hypothesi
state
increas
incid
allerg
diseas
western
world
base
higher
standard
person
cleanli
thu
reduc
opportun
cross
infect
microorgan
antibiot
may
alter
microbiom
thu
immun
matur
develop
current
intern
guidelin
support
use
antibiot
asthma
yet
antibiot
often
prescrib
gener
treatment
lower
respiratori
tract
infect
lrti
asthma
despit
evid
bacteri
viral
etiolog
antibiot
exposur
uteru
associ
increas
risk
asthma
cohort
analys
associ
tripl
antibiot
use
treat
respiratori
infect
rather
antibiot
use
either
urinari
tract
skin
infect
earli
antibiot
use
also
believ
increas
asthma
risk
fold
year
old
antibiot
may
drive
chang
microbiom
deplet
potenti
protect
microorgan
includ
prevotella
spp
contribut
airway
dysbiosi
seen
gut
affect
immun
develop
fact
could
alter
immun
respons
viral
infect
thu
predispos
ae
rate
seem
plausibl
mice
longterm
treatment
antibiot
neg
impact
immun
influenza
recent
larg
cohort
studi
significantli
higher
risk
physicianconfirm
wheez
antibiot
prescript
twofold
increas
sever
wheez
ae
antibiot
prescript
also
observ
children
wheez
risk
ae
admiss
hospit
also
significantli
increas
year
first
antibiot
prescript
children
receiv
antibiot
infanc
significantli
lower
induct
cytokin
virusinfect
pbmc
age
conclus
increas
suscept
viral
infect
associ
earli
life
antibiot
prescript
asthma
risk
although
author
could
exclud
revers
causat
antibiot
use
asthma
influenc
pbmc
respons
virus
later
life
clearli
area
emerg
interest
larg
clinic
studi
requir
understand
interrelationship
rv
asthma
copd
treatment
determin
whether
certain
treatment
benefit
respiratori
infect
asthma
predomin
rv
infect
exacerb
chronic
respiratori
diseas
must
therefor
strengthen
claim
direct
target
diseas
unfortun
success
develop
antivir
vaccin
rv
disappoint
compar
develop
success
antivir
rsv
vaccin
influenza
next
section
consid
futur
direct
target
rv
directli
consid
therapi
option
avail
may
indirectli
affect
rvinduc
host
respons
critic
exacerb
chronic
respiratori
diseas
antivir
rv
discuss
elsewher
seldom
test
individu
chronic
respiratori
diseas
earli
saw
number
rvspecif
antivir
test
healthi
volunt
howev
none
consid
efficaci
enough
transcend
earli
clinic
develop
pipelin
recent
seri
compound
act
host
nmyristoyltransferas
shown
antivir
effect
vitro
model
rv
infect
block
viru
capsid
assembl
although
efficaci
observ
compound
given
within
hour
infect
challeng
use
antivir
chronic
respiratori
diseas
asthma
copd
mani
discuss
recent
review
articl
includ
dose
treatment
time
relev
infect
relationship
viru
load
symptom
onset
durat
use
exist
therapi
potent
effect
rv
vitro
vivo
therapi
test
asthma
howev
significantli
alter
lung
function
acq
score
studi
natur
occur
infect
subgroup
analysi
asthmat
sever
diseas
experi
improv
acq
morn
pef
compar
placebo
suggest
pan
antivir
may
use
treat
ae
sever
patient
confound
factor
therapi
act
antivir
fact
may
provid
addit
therapeut
benefit
downregul
type
pathway
make
ifn
therapi
attract
therapi
ae
complic
interpret
posit
effect
fact
asthmat
may
defect
ifn
induct
make
ifntherapi
attract
may
addit
complic
interpret
trial
ifn
addit
ifninduc
agent
agonist
may
also
hold
promis
ae
downregul
type
immun
via
induc
ifn
convers
may
also
true
cytokin
therapi
show
impress
reduct
ae
rate
howev
unclear
act
reduc
ongo
type
inflamm
alon
restor
defect
ifnmedi
antivir
respons
antiig
shown
affect
ae
rate
asthmat
children
recent
studi
volunt
show
ae
rate
antiig
therapi
directli
relat
ex
vivo
level
produc
rv
infect
pbmc
mechan
may
also
relev
copd
copd
patient
may
exhibit
increas
eosinophil
infiltr
copd
clearli
care
research
need
area
use
biolog
antiig
establish
experiment
rv
challeng
studi
may
also
help
discern
true
mechan
action
asthmat
benefit
azithromycin
macrolid
antibiot
shown
promis
reduc
rate
ae
copd
reduc
number
wheez
event
lrti
young
children
fact
effect
observ
absenc
proven
bacteri
infect
intrigu
suggest
azithromycin
may
addit
benefit
mere
antibiot
one
studi
effect
obviou
volunt
proven
rv
infect
suggest
rv
may
way
suscept
azithromycin
although
secondari
bacteri
infect
may
consequ
rv
infect
studi
potenti
antivir
properti
azithromycin
support
vitro
studi
show
azithromycin
boost
rvinduc
ifn
respons
thu
reduc
viral
load
augment
ifn
specif
virusinduc
inflammatori
mediat
affect
although
mechan
remain
properli
elucid
direct
benefit
azithromycin
rv
infect
yet
proven
clinic
set
exacerb
respiratori
diseas
repres
major
unmet
need
respiratori
medicin
past
year
undoubtedli
put
respiratori
viral
infect
center
stage
trigger
exacerb
perceiv
import
increas
diagnost
test
improv
mani
challeng
still
remain
elucid
mechan
diseas
immunopatholog
identifi
atrisk
popul
optim
treatment
identifi
futur
therapeut
target
basic
research
import
direct
continu
translat
find
vitro
ex
vivo
cultur
system
anim
model
human
model
differ
respiratori
diseas
also
differ
stage
term
address
unmet
therapeut
need
subpopul
asthmat
experienc
ae
benefit
addit
antityp
cytokin
therapi
better
understand
basic
diseas
mechan
need
subgroup
new
diseas
modifi
approach
yet
appli
copd
reason
cautiou
optim
copd
may
benefit
approach
success
appli
asthma
cf
ild
repres
differ
challeng
basic
research
requir
better
understand
role
virus
underli
mechan
diseas
trigger
exacerb
two
diseas
may
also
candid
diseas
direct
antivir
therapi
